• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌与胆管癌混合型:根据细胞角蛋白表达提出的标准及临床病理特征分析

Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features.

作者信息

Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M

机构信息

Department of Pathology II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

出版信息

Hum Pathol. 1995 Sep;26(9):956-64. doi: 10.1016/0046-8177(95)90084-5.

DOI:10.1016/0046-8177(95)90084-5
PMID:7545644
Abstract

We herein evaluated 36 cases of combined hepatocellular and cholangiocarcinoma (cHCC-CC) (including 29 surgically resected and seven autopsy cases) by the immunohistochemical methods of anticytokeratin antibodies 7 and 19, and then analyzed the clinicopathologic features by comparing cHCC-CC with ordinary hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). The results indicated that even if mucin production could not be confirmed, nine cases with HCC areas that showed a histological resemblance to CC also showed immunohistological biliary differentiation. Therefore, we advocate that these HCC with biliary differentiation based on an immunohistochemical analysis should thus be included in the criteria of cHCC-CC in broad terms. Regardless of the extent of mucin production, the cHCC-CCs as indicated by an immunohistochemical analysis are considered to have a similar background to that of ordinary HCCs regarding such factors as the average age, male:female ratio, hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCVAb) positivity, alpha-fetoprotein level, and the presence of cirrhosis. However, cHCC-CCs tend to metastasize to many organs and the lymph nodes, and, as a result, have a poor prognosis.

摘要

我们在此通过抗细胞角蛋白抗体7和19的免疫组织化学方法评估了36例肝细胞癌合并胆管癌(cHCC-CC)(包括29例手术切除病例和7例尸检病例),然后通过将cHCC-CC与普通肝细胞癌(HCC)和胆管癌(CC)进行比较来分析其临床病理特征。结果表明,即使无法确认黏液分泌,9例肝细胞癌区域在组织学上与胆管癌相似的病例也显示出免疫组织学上的胆管分化。因此,我们主张基于免疫组织化学分析的这些具有胆管分化的肝细胞癌应广义上纳入cHCC-CC的标准。无论黏液分泌程度如何,免疫组织化学分析所示的cHCC-CC在平均年龄、男女比例、乙肝表面抗原(HBsAg)和丙肝病毒抗体(HCVAb)阳性率、甲胎蛋白水平以及肝硬化存在等因素方面,被认为与普通肝细胞癌具有相似的背景。然而,cHCC-CC往往会转移至多个器官和淋巴结,因此预后较差。

相似文献

1
Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features.肝细胞癌与胆管癌混合型:根据细胞角蛋白表达提出的标准及临床病理特征分析
Hum Pathol. 1995 Sep;26(9):956-64. doi: 10.1016/0046-8177(95)90084-5.
2
Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases.肝细胞癌合并胆管癌:26例手术切除病例的临床病理研究
Jpn J Clin Oncol. 2003 Jun;33(6):283-7. doi: 10.1093/jjco/hyg056.
3
Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.15例肝细胞癌合并胆管癌患者的临床病理特征
Hepatobiliary Pancreat Dis Int. 2007 Apr;6(2):161-5.
4
Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.切除的肝细胞癌合并胆管癌的艾伦C型分类的临床和病理特征:与肝细胞癌和胆管细胞癌的比较研究
J Gastrointest Surg. 2006 Jul-Aug;10(7):987-98. doi: 10.1016/j.gassur.2006.01.018.
5
The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.肝细胞癌合并胆管细胞癌、肝细胞癌和肝内胆管细胞癌术后的临床特征和预后因素:倾向评分匹配分析。
Int J Med Sci. 2021 Jan 1;18(1):187-198. doi: 10.7150/ijms.50883. eCollection 2021.
6
Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.肝细胞癌合并胆管细胞癌:临床特征、治疗方式和预后。
Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27.
7
Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.肝细胞癌-胆管癌、肝细胞癌及肝内胆管癌联合切除术后的结果
J Gastrointest Surg. 2016 Feb;20(2):411-20. doi: 10.1007/s11605-015-3045-3. Epub 2015 Dec 1.
8
Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.在肝细胞癌和胆管细胞癌合并癌中 Akt/哺乳动物雷帕霉素靶蛋白通路的激活:胆管细胞癌成分中 p-4E-BP1 表达与预后的显著相关性。
Virchows Arch. 2020 Jun;476(6):881-890. doi: 10.1007/s00428-019-02741-3. Epub 2020 Jan 11.
9
Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection.肝移植和切除术后肝细胞癌-胆管癌合并症的长期预后
Liver Transpl. 2017 Mar;23(3):330-341. doi: 10.1002/lt.24711.
10
Combined hepatocellular-cholangiocarcinoma: a clinicopathological study.肝细胞-胆管细胞癌联合:一项临床病理研究。
J Gastroenterol Hepatol. 1998 Jan;13(1):34-40. doi: 10.1111/j.1440-1746.1998.tb00542.x.

引用本文的文献

1
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management.肝细胞-胆管细胞癌:生物学、诊断与管理
Liver Cancer. 2023 Apr 24;13(1):6-28. doi: 10.1159/000530700. eCollection 2024 Feb.
2
Update on Pathologic and Radiologic Diagnosis of Combined Hepatocellular-Cholangiocarcinoma.肝细胞-胆管细胞癌联合病理与放射学诊断的最新进展
J Liver Cancer. 2021 Mar;21(1):12-24. doi: 10.17998/jlc.21.1.12. Epub 2021 Mar 31.
3
Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update.肝细胞癌-胆管癌合并症的病理学:最新进展
Cancers (Basel). 2023 Jan 13;15(2):494. doi: 10.3390/cancers15020494.
4
The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma-State of the Art and Future Perspectives.肝细胞-胆管细胞癌联合诊断方法——现状与未来展望
Cancers (Basel). 2023 Jan 1;15(1):301. doi: 10.3390/cancers15010301.
5
Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach.肝细胞-胆管细胞癌:病理学与诊断方法的最新进展
Biomedicines. 2022 Jul 29;10(8):1826. doi: 10.3390/biomedicines10081826.
6
Treatment and Survival Patterns of Primary Adenosquamous Carcinoma of the Liver: A Retrospective Analysis.肝原发性腺鳞癌的治疗与生存模式:一项回顾性分析
Front Oncol. 2021 Aug 9;11:621594. doi: 10.3389/fonc.2021.621594. eCollection 2021.
7
Efficacy of expressions of Arg-1, Hep Par-1, and CK19 in the diagnosis of the primary hepatocellular carcinoma subtypes and exclusion of the metastases.Arg-1、Hep Par-1 和 CK19 表达在原发性肝细胞癌亚型诊断中的作用及对转移瘤的排除。
Histol Histopathol. 2021 Sep;36(9):981-993. doi: 10.14670/HH-18-361. Epub 2021 Jul 13.
8
A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma.肝细胞-胆管细胞癌联合诊断与治疗的现代方法
Curr Hepatol Rep. 2020 Dec;19(4):478-485. doi: 10.1007/s11901-020-00556-4. Epub 2020 Oct 31.
9
Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis.联合肝细胞癌和胆管细胞癌与肝细胞癌和胆管细胞癌患者术后临床特征和结局的比较:倾向评分匹配分析。
BMC Gastroenterol. 2021 Jan 7;21(1):20. doi: 10.1186/s12876-020-01586-4.
10
Elevated neutrophil-to-lymphocyte ratio and predominance of intrahepatic cholangiocarcinoma prediction of poor hepatectomy outcomes in patients with combined hepatocellular-cholangiocarcinoma.中性粒细胞与淋巴细胞比值升高和肝内胆管细胞癌为主型与合并肝细胞癌-胆管细胞癌患者肝切除术后不良结局相关。
PLoS One. 2020 Dec 11;15(12):e0240791. doi: 10.1371/journal.pone.0240791. eCollection 2020.